Clinical Trial Update: Rifaximin for Chronic Immune Activation in People With HIV [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating rifaximin for chronic immune activation in people with HIV, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HIV | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-24